New bispecific antibodies in diffuse large B-cell lymphoma
The CD20xCD3 T-cell-engaging bispecific antibodies are a highly active new treatment option for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Epcoritamab and glofitamab have both been approved in over thirty countries as monotherapy for DLBCL after two prior treatment...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Ferrata Storti Foundation
2025-02-01
|
| Series: | Haematologica |
| Online Access: | https://haematologica.org/article/view/11929 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|